We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Classification Categories, Formal Meetings Under BsUFA III Explained in Draft Guidances
Classification Categories, Formal Meetings Under BsUFA III Explained in Draft Guidances
Two draft guidances with the FDA’s recommendations for Biosimilar User Fee Act (BsUFA III) classification categories and preparation for formal meetings with agency staff were issued today.